Another Day, Another GI Bug

Author(s):  
Pinaki Mukherji ◽  
Dana Libov

This chapter presents 3 cases of vomiting in children and explores less common diagnoses not to be missed by the astute clinician. The first case of a child with recurrent progressive vomiting has unusual lab abnormalities which leads to the final diagnosis of an inborn error of metabolism. The second case presents a child with several Emergency Department visits for vomiting and a skin finding leads to a final diagnosis of non-accidental trauma. The final case reviews a vomiting child with electrolyte abnormalities and an abnormal radiograph, leading to a diagnosis of malrotation with volvulus. Each case gives the clinician key pearls to distinguish these high risk cases from everyday gastroenteritis.

2019 ◽  
pp. 082585971986906
Author(s):  
Debbie Selby ◽  
Anita Chakraborty ◽  
Audrey Kim ◽  
Jeff Myers

Background: Emergency department visits or readmission to hospital are common particularly among those with advanced illness. Little prospective data exist on early outcomes specifically for patients seen by a palliative care consult service during their acute care admission, who are subsequently discharged home. Methods: This study followed 62 oncology patients who had had a palliative care consult during their admission to acute care with weekly phone calls postdischarge for 4 weeks. Events recorded included death, readmission, emergency department visits, and admission to a palliative care unit. Results: By the end of the study, 32 (52%) of 62 had had at least 1 event, (readmission, emergency department visit, or death), with the majority of these occurring in the first 2 weeks postdischarge. The overall 4-week death rate was 14 (22.6%) of 62. Conclusions: These data suggest that the need for a palliative care consult identifies inpatients at very high risk for early deterioration and underlines the critical importance of advance care planning/goals-of-care discussions by the oncology and palliative care teams to ensure patients and families understand their disease process and have the opportunity to direct their care decisions.


2016 ◽  
Vol 214 (1) ◽  
pp. S278
Author(s):  
Jean-Ju Sheen ◽  
Peter S. Bernstein ◽  
Brian Tu ◽  
Ying Liu ◽  
Desmond Sutton-Ramsey ◽  
...  

Author(s):  
Douglas S Corwin ◽  
Peter T Ender ◽  
Nitasa Sahu ◽  
Ryan A Durgham ◽  
Dennis M McGorry ◽  
...  

Abstract Bamlanivimab, a monoclonal antibody targeting the spike protein of SARS-CoV-2, is available for ambulatory treatment of COVID-19. This real-world study confirms the efficacy of bamlanivimab in reducing hospital admissions and emergency department visits among high-risk outpatients with mild to moderate COVID-19 illness and reveals a trend toward improved mortality.


2009 ◽  
Vol 2009 ◽  
pp. 1-3 ◽  
Author(s):  
Alexander A. C. Leung ◽  
Alicia K. Chan ◽  
Justin A. Ezekowitz ◽  
Alexander K. C. Leung

3-hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) lyase deficiency is an inborn error of metabolism characterized by impairment of ketogenesis and leucine catabolism resulting in an organic acidopathy. In 1994, a case of dilated cardiomyopathy and fatal arrhythmia was reported in a 7-month-old infant. We report a case of dilated cardiomyopathy in association with HMG CoA lyase deficiency in a 23-year-old man with the acute presentation of heart failure. To our knowledge, this is the first case reported in an adult.


2021 ◽  
Author(s):  
Brandon J Webb ◽  
Whitney Buckel ◽  
Todd Vento ◽  
Allison M Butler ◽  
Nancy Grisel ◽  
...  

Importance: Interventions to reduce hospitalization of patients with COVID-19 are urgently needed. Randomized trials for efficacy suggest that anti-SARS-CoV2 neutralizing monoclonal antibodies (MAb) may reduce medically-attended visits and hospitalization but effectiveness has not been confirmed in a real-world setting. Objective: Estimate the effectiveness of MAb infusion in a real-world cohort of ambulatory patients with early symptomatic COVID-19 at high risk for hospitalization. Design: Quasi-experimental observational cohort study using target trial emulation and causal inference methodology in pre-and post-implementation groups. Setting: Infusion centers and urgent care clinics within an integrated healthcare system in the United States Participants: 13,534 high-risk adult outpatients with symptomatic, laboratory-confirmed COVID-19 within 7 days of symptom onset. Exposures: A single intravenous infusion of either bamlanivimab 700 mg or casirivimab/imdevimab 1200 mg/1200 mg. Main Outcomes and Measures: The primary outcome was emergency department visit or hospitalization within 14 days of positive test. Patients who received MAb infusion were compared to contemporaneous controls using inverse probability of treatment weighting, and to a pre-implementation cohort using propensity-weighted interrupted time series analysis. An exploratory analysis compared effectiveness of casirivimab/imdevimab and bamlanivimab. Results: 7404 patients who would have been MAb-eligible were identified in a pre-implementation cohort (July 1-November 27, 2020). In the post-implementation period (November 28, 2020-January 28, 2021), 594 received MAb treatment and 5536 MAb-eligible patients did not. Among Mab recipients, 479 (80.6%) received bamlanivimab and 115 (19.4%) casirivimab/imdevimab. The primary outcome occurred in 75 (12.6%) MAb recipients, 1018 (18.4%) contemporaneous controls, and 1525 (20.6%) patients in the pre-implementation cohort. MAb treatment was associated with fewer subsequent emergency department visits and hospitalizations (odds ratio estimating the average treatment effect 0.69, 95% CI 0.60-0.79). After implementation, propensity-weighted probability of emergency department visit or hospitalization decreased by 0.7% per day (95% CI 0.03-0.10%, p<0.001). Overall, 7 (1.2%) MAb patients experienced an adverse event; two (0.3%) were considered serious. In the exploratory analysis, the effect of casirivimab/imdevimab versus bamlanivimab was not significant (OR 0.52, 95% CI 0.17-1.63, p=0.26). Conclusions and Relevance: MAb treatment of high-risk ambulatory patients with early COVID-19 was well-tolerated and effective at preventing the need for subsequent medically-attended care.


Stroke ◽  
2013 ◽  
Vol 44 (suppl_1) ◽  
Author(s):  
Anne Cayley ◽  
Jemini Abraham ◽  
Libby Kalman ◽  
Cheryl Jaigobin ◽  
Martin del Campo ◽  
...  

Background: About one in four ischemic strokes are preceded by a TIA; 43% of TIAs occur within one week before stroke. Patients with a TIA require urgent assessment, risk stratification, and preventative treatment, but often cannot access a Stroke Prevention Clinic in a timely fashion. Therefore, these patients are often admitted to hospital for evaluation but it is unclear if inpatient evaluation is optimal or specifically necessary for this patient population. Methods: We developed a novel high-risk TIA and Minor Stroke (TAMS) day-unit to provide rapid access to patient assessment, investigations, initiation of prevention strategies, and stroke prevention education. The TAMS Unit patient assessments were based on a collaborative model led by stroke Nurse Practitioners and an attending stroke Neurologist. All patients had cerebrovascular imaging (CT angiography, MR angiography, or carotid Doppler if there were exclusions to CT or MR angiography), and as appropriate, echocardiography and Holter monitoring initiated at the TAMS Unit visit. We evaluated the feasibility of this novel care model. Outcomes including time to assessment, investigations, and treatment for high-risk TIA/stroke etiologies and stroke risk factors, as well as return emergency department visits or readmissions within 30 days were assessed. Results: Between Sept. 6, 2011 and Aug. 8, 2012, 142 patients were seen in the TAMS Unit. Median time from emergency department visit to TAMS Unit assessment was 1 day. The final diagnosis was TIA in 41% of patients and minor stroke (NIHSS < 4) in 27.5% of patients. Atrial fibrillation was diagnosed in 8 (5.6%) patients; anticoagulation was initiated promptly upon diagnosis. High-grade carotid stenosis was diagnosed in 4 (2.8%) patients and these patients were referred for urgent endarterectomy. There were 12 (8.5%) patients that had a return visit to the emergency department within 30 days; 2 (1.4%) with stroke, 8 (5.6%) with recurrent TIA or fluctuating symptoms, and 2 (1.4%) with other diagnoses. Conclusion: Our novel TAMS Unit is a feasible care model that provides rapid access to assessment and treatment of high-risk TIA and minor stroke patients, and is another level of care between hospital admission and the outpatient Stroke Prevention Clinic.


2019 ◽  
Vol 22 (5) ◽  
pp. 394-398
Author(s):  
Brooke E. Salzman ◽  
Rachel V. Knuth ◽  
Amy T. Cunningham ◽  
Marianna D. LaNoue

Sign in / Sign up

Export Citation Format

Share Document